Prescription medicine
Eluxadoline Brand names: Viberzi
Eluxadoline (Viberzi) is a prescription medicine with an FDA approval on record since 2015. No generic is listed; pharmacies paid $28.09 per Viberzi 100 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
- DEA Schedule IV
Check it at the source: the eluxadoline FDA label on DailyMed (effective July 16, 2024, Allergan, Inc.); the NDA 206940 record on Drugs@FDA; every eluxadoline label on DailyMed.
Highlights of the record
FDA label of July 16, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageVIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Forms and strengths
- 75 mg
- 100 mg
Film-coated tablet.
On the market
- Earliest approval on file
- May 27, 2015 Viberzi, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 2 first March 14, 2025; 0 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- March 14, 2033 Viberzi tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $28.09 per tablet Viberzi 100 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 2,928 through July 30, 2026
What is eluxadoline used for?
From the label: indications and usageVIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). VIBERZI is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Conditions named in the indications of eluxadoline's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: mu-Opioid Receptor Agonist.
Source: FDA drug label (Viberzi), NDA206940 (Abbvie), as published by Allergan, Inc., effective July 16, 2024 (SPL set 7821bd40-4c84-4984-951b-6436ae20421a), via openFDA; the full label on DailyMed
What does the patient leaflet for eluxadoline say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about VIBERZI?VIBERZI can cause serious side effects, including: Inflammation of the pancreas (pancreatitis). Pancreatitis has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder. Pancreatitis usually happens within the first week of treatment with VIBERZI but can happen after 1 to 2 doses of VIBERZI. Your risk of getting pancreatitis is increased if you drink more than 3 alcoholic drinks a day. Limit your use of alcoholic drinks while you are taking VIBERZI. Sphincter of Oddi spasm. The sphincter of Oddi is a muscular valve that controls the flow of digestive juices (bile and pancreatic juice) to the first part of your small intestine. A sphincter of Oddi spasm can cause an increase in your liver and pancreas enzymes and inflammation of the pancreas (pancreatitis) that can cause sudden stomach-area (abdomen) pain. […] Stop taking VIBERZI right away and get emergency medical care if you have signs or symptoms of an allergic reaction, including: ○ swelling of your face, lips, mouth or tongue ○ itching ○ shortness of breath or other breathing problems ○ rash ○ hives Constipation. Constipation, including severe constipation that can lead to hospitalization has happened after taking VIBERZI. Stop taking VIBERZI and call your doctor right away if you develop severe constipation while taking VIBERZI. […]
From the patient leaflet: What should I avoid while taking VIBERZI?Limit your use of alcoholic drinks while you are taking VIBERZI. If you have liver problems, do not drive, operate machinery, or do other dangerous activities until you know how VIBERZI affects you.
From the patient leaflet: How should I store VIBERZI?Store VIBERZI at room temperature between 68°F to 77°F (20°C to 25°C). Keep VIBERZI and all medicines out of the reach of children. General Information about the safe and effective use of VIBERZI . Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VIBERZI for a condition for which it was not prescribed. Do not give VIBERZI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your doctor or pharmacist for information about VIBERZI that is written for health professionals.
Source: FDA drug label (Viberzi), NDA206940 (Abbvie), as published by Allergan, Inc., effective July 16, 2024 (SPL set 7821bd40-4c84-4984-951b-6436ae20421a), via openFDA; the full label on DailyMed
Is there a generic for eluxadoline (Viberzi)?
The FDA approved the first generic eluxadoline on March 14, 2025. 2 generic applications are approved; 0 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 14 patents for Viberzi tablets: the compound patent runs to May 27, 2029, and the last listed entry to March 14, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2015 earliest approval on file
- 2025 first generic approved
- 2033 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for eluxadoline (Viberzi)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $28.09 per Viberzi 100 mg tablet, up 5% from $26.80 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Viberzi 100 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Viberzi 100 mg tablet | Brand | $28.09 per tablet | $842.80 | +5% |
| Viberzi 75 mg tablet | Brand | $28.10 per tablet | $843.11 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the eluxadoline label say about other medicines?
The eluxadoline label names 9 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Alosetron | drug interactions | Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions … use. Discontinue loperamide immediately if constipation occurs. Examples: alosetron, anticholinergics, opioids |
| Atazanavir | drug interactions | OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine [ see Clinical Pharmacology () ] … Adverse Reactions ()]. Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag |
| Cyclosporine | drug interactions | OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine [ see Clinical Pharmacology () ] … eluxadoline-related adverse reactions [see Adverse Reactions ()]. Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag |
| Eltrombopag | drug interactions | OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine [ see Clinical Pharmacology () ] … antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag |
| Gemfibrozil | drug interactions | OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine [ see Clinical Pharmacology () ] … eluxadoline-related adverse reactions [see Adverse Reactions ()]. Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag |
| Loperamide | drug interactions | Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions Intervention: Avoid use with other drugs that may cause constipation (see below); loperamide may be used occasionally for acute management of severe diarrhea but avoid chronic use. … |
| Rifampin | drug interactions | OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine [ see Clinical Pharmacology () ] … antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag |
| Ritonavir | drug interactions | OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine [ see Clinical Pharmacology () ] … Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag |
| Rosuvastatin | drug interactions | Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rhabdomyolysis [ see Clinical Pharmacology … Intervention: Use the lowest effective dose of rosuvastatin (see prescribing information of rosuvastatin for additional information on recommended dosing). … |
Source: FDA drug label (Viberzi), NDA206940 (Abbvie), as published by Allergan, Inc., effective July 16, 2024 (SPL set 7821bd40-4c84-4984-951b-6436ae20421a), via openFDA; the full label on DailyMed
What do FAERS reports show for eluxadoline?
The FDA Adverse Event Reporting System holds 2,928 reports that list eluxadoline among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 66 are coded as a death and 563 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as eluxadoline?
5 other medicines are given the same way (oral) and in the same FDA class as eluxadoline or labeled mainly for the same use (irritable bowel syndrome), the same class first. Irritable bowel syndrome lists all 7 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Dicyclomine | Irritable bowel syndrome | 37 labelers | $0.059 per tablet 20 mg tablet | No current entry |
| Chlordiazepoxide and clidinium | Irritable bowel syndrome | 12 labelers | $0.256 per capsule Chlordiazepoxide-clidinium capsule | No current entry |
| Rifaximin | Irritable bowel syndrome, Diarrhea | none listed | n/a | No current entry |
| Tenapanor | Irritable bowel syndrome | none listed | $32.54 per tablet 50 mg tablet | No current entry |
| Linaclotide | Irritable bowel syndrome | none listed | $9.02 per capsule 145 mcg capsule | No current entry |
Every medicine labeled for the same conditions as eluxadoline
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to eluxadoline
- 5 medicines for the same use
- Eluxadoline side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other